Seres Therapeutics Mcrb Ser 287 Phase 1b Topline Study Results In However, important compositional and potential therapeutic differences exist between the investigational drugs. ser 287 is a donor derived product candidate, whereas ser 301 utilizes seres’ next generation technology and is based on rationally designed, cultivated consortia of bacteria. About ser 287. ser 287 is an oral, biologically derived microbiome therapeutic candidate designed to have pharmacological effects on multiple pathways relevant to ulcerative colitis that can be modulated by the gastrointestinal microbiome. seres has obtained fda fast track designation for ser 287 in active mild to moderate uc.
Seres Ser 287 Investigational Oral Biologically Derived About ser 287. ser 287 is an oral, biologically derived microbiome therapeutic candidate designed to have pharmacological effects on multiple pathways relevant to ulcerative colitis that can be. Participants received 6 days of preconditioning with oral vancomycin (125 mg, 4 times daily) or placebo followed by 8 weeks of oral ser 287 or placebo. patients were randomly assigned (2:3:3:3) to groups that received placebo followed by either placebo or ser 287 once weekly, or vancomycin followed by ser 287 once weekly, or ser 287 once daily. Seres therapeutics has published positive data analyses from its phase ib trial of ser 287 in patients with active mild to moderate ulcerative colitis (uc). an oral biologically derived microbiome therapeutic candidate, ser 287 is designed to have pharmacological effects on various pathways significant to ulcerative colitis that can be. Live biotherapeutic formulated for oral dosing composed of. firmicute spores associated with gut health. bacterial spores are resistant to gastric acid allowing easy formulation into capsules for effective colonic delivery. designed to to impact multiple molecular networks key to gut barrier and immunomodulatory functions.
Ser 287 An Investigational Microbiome Therapeutic For Patients With Seres therapeutics has published positive data analyses from its phase ib trial of ser 287 in patients with active mild to moderate ulcerative colitis (uc). an oral biologically derived microbiome therapeutic candidate, ser 287 is designed to have pharmacological effects on various pathways significant to ulcerative colitis that can be. Live biotherapeutic formulated for oral dosing composed of. firmicute spores associated with gut health. bacterial spores are resistant to gastric acid allowing easy formulation into capsules for effective colonic delivery. designed to to impact multiple molecular networks key to gut barrier and immunomodulatory functions. About ser 287 ser 287, an investigational oral microbiome therapeutic candidate consisting of a consortium of highly purified firmicute spores, is designed to normalize the gastrointestinal. Ser 155 is an oral, investigational microbiome therapy consisting of cultivated live bacteria designed to prevent enteric derived bloodstream infections and reduce the incidence of graft versus host disease (gvhd) by restructuring the microbiome, decolonizing pathogens, and restoring key immunomodulating functions.
Seres Ser 287 For Ulcerative Colitis Shows Positive Results In Early Trial About ser 287 ser 287, an investigational oral microbiome therapeutic candidate consisting of a consortium of highly purified firmicute spores, is designed to normalize the gastrointestinal. Ser 155 is an oral, investigational microbiome therapy consisting of cultivated live bacteria designed to prevent enteric derived bloodstream infections and reduce the incidence of graft versus host disease (gvhd) by restructuring the microbiome, decolonizing pathogens, and restoring key immunomodulating functions.
Comments are closed.